TVGN

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Retrieved on: 
Thursday, April 11, 2024
TVGN, Cancer, Cell, Woman, MD, Virology, Lymphoma, Therapy, Neurology, Virus, HPV, EBV, Clinical trial, Viral, Cervical cancer, Vaccine

Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.

Key Points: 
  • Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.
  • WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings (Tevogen) ( Nasdaq : TVGN ), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
  • Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explains the company’s oncology pipeline strategy.
  • Additional approaches are in development to take this approach even further in the treatment of other cancers.”

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Retrieved on: 
Wednesday, March 20, 2024
COVID-19, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, TVGN, COVID, Mutation, Immunotherapy, Patient, DNP, SARS-CoV-2, Genome, Peptide

Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.

Key Points: 
  • Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.
  • TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides.
  • TVGN 489’s peptide targets have been preserved in all previously studied COVID strains.
  • Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, including the currently dominant JN.1 strain and newer JN.1 strains, show that 96% of these CTLs remain active against the current circulating variants.

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, SARS-CoV-2, HLA, MD, Infection, Cell, Risk, CTL, Genome, COVID, Patient, Clinical trial, TVGN, Vaccine

TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.

Key Points: 
  • TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.
  • Tevogen plans to assess whether TVGN 489 cells can rapidly eliminate symptoms of Long Covid.
  • Prior to launching the Long COVID clinical trial, Tevogen seeks to address whether Long COVID occurs more commonly with certain HLA types and less commonly with others, or whether Long COVID occurs randomly in the population regardless of HLA.
  • I am highly optimistic that TVGN 489 will offer a meaningful solution for both acute and Long COVID patients,” said Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer.

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

Retrieved on: 
Wednesday, February 14, 2024
Therapy, Virology, Health, Cancer, Chairperson, Antigen, DSM-IV codes, Infection, TVGN, Neurology

Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

Key Points: 
  • Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.
  • WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc.
  • The combined company’s common stock and warrants will begin trading on Nasdaq Global Market (“Nasdaq”) under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024.
  • The listing with Nasdaq is expected to provide Tevogen Bio increased access to capital to accelerate the development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation

Retrieved on: 
Thursday, June 29, 2023
Long COVID, Infection, Weapon, Antigen, Partnership, Therapy, Semper paratus, Virology, COVID-19, Clinical trial, Cancer, Semper, Multiple sclerosis, Immunotherapy, TVGN, LGST, Acquisition, Transaction, Viral, Cytotoxic T cell, Growth, Immunodeficiency, Health, MPH, Neurology, NYSE, Safety, Vaccine, Pharmaceutical industry, Management, MD

Tevogen Bio, along with its founder, has received broad recognition for its innovative, patient-first approach in the biopharma industry.

Key Points: 
  • Tevogen Bio, along with its founder, has received broad recognition for its innovative, patient-first approach in the biopharma industry.
  • Upon closing of the merger (the “Transaction”), the combined company will be named Tevogen Bio Holdings Inc. (“Tevogen Holdings”).
  • Tevogen Holdings common stock and warrants are expected to be listed on the NYSE under the new ticker symbol “TVGN”.
  • Additionally, the Transaction includes a contingent earnout in the form of additional equity in Tevogen Holdings payable to the Tevogen Bio stockholders and Semper Paratus’ sponsor.

Tevogen Bio will Present Positive Proof-of-Concept Trial Findings at the 5th Annual Allogeneic Cell Therapies Summit in Boston, MA

Retrieved on: 
Monday, May 22, 2023
Science, Biotechnology, Research, Health, COVID-19, Infectious Diseases, Genetics, Clinical Trials, Infection, Weapon, Antigen, Cytokine release syndrome, Omicron, Bio, SARS-CoV-2, Principal investigator, Health status of Asian Americans, Clinical trial, Cancer, Viral, Multimedia, DNP, TVGN, Incidence, Genome, MD, Patient, Thomas Jefferson University Hospital, Viral load, Cytotoxic T cell, Clinical, PCR, Safety, Pharmaceutical industry, Vaccine, Long COVID

Tevogen Bio is pleased to announce that it will present the proof-of-concept clinical trial results of TVGN 489, the company's first clinical product from its ExacTcell platform , at the 5th Annual Allogeneic Therapies Summit in Boston, MA.

Key Points: 
  • Tevogen Bio is pleased to announce that it will present the proof-of-concept clinical trial results of TVGN 489, the company's first clinical product from its ExacTcell platform , at the 5th Annual Allogeneic Therapies Summit in Boston, MA.
  • CD8+ CTLs in ExacTcell based products target multiple and distinct antigens to overcome potential mutational challenges, such as TVGN 489.
  • “We believe that cell therapies are expected to be the norm, not the exception,” said Tevogen CEO Ryan Saadi, M.D., M.P.H.
  • “Tevogen aspires and is designed to be the very first biotech to achieve commercial success and patient affordability through advanced science and efficient business models.”

Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform

Retrieved on: 
Monday, January 23, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Biotechnology, Long COVID, Viral load, Hope, Viral, Cancer, TVGN, Patient, POC, MPH, Monitoring, Immunodeficiency, DNP, Principal, Pharmaceutical industry, Vaccine, Safety, MD

Based on the data in Table 1, safety was confirmed with the minimum required number of patients per dosing level.

Key Points: 
  • Based on the data in Table 1, safety was confirmed with the minimum required number of patients per dosing level.
  • Enrollment was completed in nine months, and six-month follow-up for all patients concluded on January 19, 2023.
  • There were no incidences of COVID-19 reinfection or Long COVID observed in any treated patient through the 6-month follow-up period.
  • Tevogen’s research pipeline includes treatment for other serious viral infections and cancers using their precision T Cell platform.

Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options

Retrieved on: 
Wednesday, December 7, 2022
COVID-19, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Genome, TVGN, Virus, Severe acute respiratory syndrome coronavirus 2, Immunodeficiency, Development, POC, Research, Patient, Virology, COVID, CTL, Degenerative disease, Neurology, Medicine, Cancer, Bio, COVID-19, Cell, Immunity, BQ, Hope, Malignancy, Risk, Pharmaceutical industry, Vaccine

There exists a significant unmet need for the treatment of COVID-19 in immunocompromised patients.

Key Points: 
  • There exists a significant unmet need for the treatment of COVID-19 in immunocompromised patients.
  • Currently, there are very few treatment options that have not been impacted by variants or are suitable for this patient population due to possible medication interactions.
  • The lack of treatment options places immunocompromised patients at higher risk of developing poor outcomes if infected with SARS-CoV-2, said Dr. Flomenberg .
  • Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Pharmaceutical, Health, COVID-19, Patient, Omicron, Clinical trial, POC, Cell, Bio, Science, Cancer, Severe acute respiratory syndrome coronavirus 2, Virus, Medicine, COVID, CTLS, CTL, Virology, Genome, Protein, Immunodeficiency, COVID-19, Neurology, TVGN, Hope, Malignancy, Degenerative disease, Pharmaceutical industry, Vaccine, Long COVID, Delta

Tevogen Bio , a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology announced today its intention to study potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in Long COVID.

Key Points: 
  • Tevogen Bio , a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology announced today its intention to study potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in Long COVID.
  • The finding that none of the patients in the TVGN 489 Proof-of-Concept (POC) trial, treated for their initial COVID infection, developed Long COVID to date is leading Tevogen to explore the potential of TVGN 489 to also treat Long COVID.
  • Im greatly encouraged by the POC trial experience of TVGN 489 and hopeful that our investigational COVID-19 therapy will eventually offer hope to a substantial segment of Long COVID patients.
  • Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to alleviate the suffering from Long COVID, said Tevogen CEO Ryan Saadi , M.D., M.P.H.